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A B S T R A C T
Background
Gestational diabetes mellitus (GDM) is associated with a range of adverse pregnancy outcomes for mother and infant. The prevention
of GDM using lifestyle interventions has proven difficult. The gut microbiome (the composite of bacteria present in the intestines)
influences host inflammatory pathways, glucose and lipid metabolism and, in other settings, alteration of the gut microbiome has been
shown to impact on these host responses. Probiotics are one way of altering the gut microbiome but little is known about their use in
influencing the metabolic environment of pregnancy.
Objectives
To assess the effects of probiotic supplementation when compared with other methods for the prevention of GDM.
Search methods
We searched the Cochrane Pregnancy and childbirth Group’s Trials Register (31 August 2013) and reference lists of the articles of
retrieved studies.
Selection criteria
Randomised and cluster-randomised trials comparing the use of probiotic supplementation with other methods for the prevention of
the development of GDM. Cluster-randomised trials were eligible for inclusion but none were identified. Quasi-randomised and cross-
over design studies are not eligible for inclusion in this review. Studies presented only as abstracts with no subsequent full report of
study results would also have been excluded.
Data collection and analysis
Two review authors independently assessed study eligibility, extracted data and assessed risk of bias of included study. Data were checked
for accuracy.
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Main results
Eleven reports (relating to five possible trials) were found. We included one study (six trial reports) involving 256 women. Four other
studies are ongoing.
The included trial consisted of three treatment arms: probiotic with dietary intervention, placebo and dietary intervention, and dietary
intervention alone; it was at a low risk of bias. The study reported primary outcomes of a reduction in the rate of gestational diabetes
mellitus (risk ratio (RR) 0.38, 95% confidence interval (CI) 0.20 to 0.70), with no statistical difference in the rates of miscarriage/
intrauterine fetal death (IUFD)/stillbirth/neonatal death (RR 2.00, 95% CI 0.35 to 11.35). Secondary outcomes reported were a
reduction in infant birthweight (mean difference (MD) -127.71 g, 95% CI -251.37 to -4.06) in the probiotic group and no clear
evidence of increased risk of pretermdelivery (RR3.27, 95%CI 0.44 to 24.43), or caesarean section rate (RR1.23, 95%CI 0.65 to 2.32).
The primary infant outcomes of rates of macrosomia and large-for-gestational age infants were not reported. The following secondary
outcomes were not reported: maternal gestational weight gain, pre-eclampsia, and the long-term diagnosis of diabetes mellitus; infant
body composition, shoulder dystocia, admission to neonatal intensive care, jaundice, hypoglycaemia and long-term rates of obesity and
diabetes mellitus.
Authors’ conclusions
One trial has shown a reduction in the rate of GDM when women are randomised to probiotics early in pregnancy but more uncertain
evidence of any effect on miscarriage/IUFD/stillbirth/neonatal death. There are no data on macrosomia. At this time, there are
insufficient studies to perform a quantitative meta-analysis. Further results are awaited from four ongoing studies.
P L A I N L A N G U A G E S U M M A R Y
Probiotics to prevent gestational diabetes mellitus
Gestational diabetes mellitus is a condition where the mother has high blood sugar levels during pregnancy. It is associated with a range
of adverse pregnancy outcomes for the mother, such as pre-eclampsia (high blood pressure with protein in the urine) and instrumental
or operative delivery, as well as for the infants who may be born large-for-gestational age. Current treatment includes diet with or
without medication. Prevention of this condition would be preferable to treatment. Preventative diet and lifestyle interventions are
time consuming and do not always reduce the number of women getting gestational diabetes. Probiotics - ’good’ bacteria that are
usually taken in the form of capsules or drinks - supplement the gut bacteria. They have the potential to change a person’s metabolism
and so prevent gestational diabetes mellitus. This review was designed to look at whether there is evidence to show if this is true or
not. At the moment there is only one randomised controlled study, which involved 256 women. This study does show a lower rate
of gestational diabetes mellitus in women who took probiotics from early pregnancy, with the rate of diagnosis of gestational diabetes
mellitus being reduced by two-thirds and their babies on average weighed 127 g less at birth. This study did not find differences in
the rates of miscarriage, intrauterine or neonatal death or stillbirth. There was no clear evidence of a change in the proportion of
women delivered by caesarean section or in the risk of preterm delivery. The study did not report on how much weight the mothers
gained during pregnancy or how many babies were large-for-gestational age or that weighed more than 4000 g at birth or on the body
composition of the babies. One study is not enough to draw any definite conclusions at the moment. There are other studies underway.
B A C K G R O U N D
Description of the condition
Gestational diabetes mellitus (GDM) is currently defined as car-
bohydrate intolerance first diagnosed during pregnancy (Hadar
2009). There are a number of different diagnostic criteria world
wide (Table 1). Rates of GDM are increasing in the obstetric pop-
ulation of both the developed (ACOG Committee 2005; Moore
2010) and developingworld (Hossain 2007; Seshiah 2008), driven
by increasing rates of overweight and obesity. Applying the new
International Association of the Diabetes and Pregnancy Study
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Groups (IADPSG) diagnostic criteria, 18% of pregnancies in the
United States are affected byGDM(HAPO2008). India andother
developing nations are also seeing an increase with rates varying
from ~ 18% in urban populations to 10% in rural populations
(Seshiah 2008).
GDM is associated with increased rates of maternal and fetal mor-
bidity and mortality, both during the pregnancy and in the longer
term (Davey 2005). Maternal pregnancy complications include
pre-eclampsia (a syndrome of hypertension and proteinuria) and
instrumental or operative delivery. Fetal complications include
macrosomia (birthweight greater than 4000 g), polyhydramnios
(excessive amniotic fluid), preterm birth, shoulder dystocia (ob-
struction of vaginal delivery by the infant’s shoulder), and neonatal
complications of admission to high-level care, respiratory distress,
hypoglycaemia (lowblood sugar), and jaundice. Bothwomenwith
GDM and their infants are at increased risk of diabetes mellitus
and metabolic dysfunction later in life (Shah 2008; Vohr 2008).
Treatment of GDM improves pregnancy outcomes with signifi-
cant reductions in the rate of serious perinatal outcomes including
macrosomia, shoulder dystocia and caesarean delivery (Crowther
2005; Landon 2009). Current management practices for GDM
are expensive but also cost effective for healthcare systems in the
short and longer term (Ohno 2011). Primary prevention of GDM
rather than treatment would however be ideal in preventing both
the economic and health costs associated with GDM.
Efforts to prevent GDM have focused on lifestyle interventions
(including diet and exercise) (Chuang 2010). These interventions
have proven challenging, both to perform and in the analysis of
effect due to heterogeneity, small study size, limited patient ad-
herence to the intervention and methodological issues. Also, it is
known that adherence to even simple measures such as folate sup-
plementation is poor (Callaway 2009). Recent systematic reviews
have concluded that no firm statement on the utility of nutritional
interventions in controlling maternal weight or preventing GDM
can be made (Dodd 2010; Streuling 2010). A Cochrane review
examining the use of dietary advice in pregnancy for prevention
of GDM has found that a low glycaemic diet was beneficial for
some outcomes including a reduced rate of large-for-gestational-
age infants; the results from the review were inconclusive (Tieu
2008). Another Cochrane review examining the utility of exer-
cise is currently underway (Han 2011). Therefore, even if com-
plex lifestyle intervention strategies were shown to prevent GDM,
compliance with these interventions for the general population
would be low. If probiotic supplementation were shown to be an
effective method of reducing rates of GDM, there would be con-
siderable benefits through improving maternal health and reduc-
ing pregnancy complications as well as a potential reduction in
health service costs related to the management of GDM.
Description of the intervention
The World Health Organization defines probiotics as “microor-
ganisms ... able to confer defined health benefits on the host”
(FAO/WHO 2001). Most probiotic products are either in food
items (such as fermented milks or yogurts available in the su-
permarkets) or supplied as dietary supplements that typically are
for sale in health food stores, pharmacies or natural food grocery
stores. These products vary considerably in their microbial com-
position and number (dosage) of viable bacteria. Interventions of
oral intake of probiotics in any form during pregnancy will be
included for the review.
How the intervention might work
The relationship between diet, host metabolism and gut micro-
biome (the variety of bacterial strains in the gut) is multidirec-
tional. Diet can influence microbiotal composition and gene ex-
pression as well as altering host metabolism directly. Altering the
gut microbiome directly can also influence the host, including al-
tering ease of nutrient absorption (Turnbaugh 2006), and influ-
encing host inflammatory pathways, glucose and lipidmetabolism
(Backhed 2004; Musso 2010). Inflammation has been implicated
in preterm labour and probiotics have been used in the prevention
of preterm labour with inconclusive results (Othman 2007).
Obesity (Backhed 2009) and type 2 diabetes (Larsen 2010) are as-
sociated with divergent changes in the gut microbiome (the com-
posite of bacteria present in the intestines). The gut microbiome
in obese rodents and humans shows an overall decrease in mi-
crobiotal diversity, with an increase in Firmicutes phylum of bac-
teria, mainly of the Mollicutes class and a fall in the species be-
longing to the Bacteroidetes phylum of bacteria (Turnbaugh 2008;
Turnbaugh 2009). Patients with type 2 diabetes have significantly
reduced numbers of species belonging to the Firmicutes phylum.
The ratio of Bacteroidetes:Firmicutes species in type 2 diabetes cor-
relates positively with plasma glucose concentration but not body
mass index. Bacteroidetes species are Gram negative bacteria, con-
taining lipopolysaccharides in their outer wall, which could con-
tribute to insulin resistance (Larsen 2010). A trial of supplemen-
tation of the probiotic strain Lactobacillus acidophilus NCFMTM
in men with type 2 diabetes showed a preservation of insulin sen-
sitivity but no change in inflammatory markers over a four-week
period (Andreasen 2010). Improvements in glycaemia and lipids
have been reported in other trials of probiotics in type 2 diabetes
(Ejtahed 2012; Moroti 2012). Women with GDM are known to
be at high risk of developing type 2 diabetes, and have a simi-
lar abnormal insulin resistance and alteration in lipid metabolism
(Davey 2005). The gut microbiome has not been explored in
GDM.
Why it is important to do this review
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A recent study examining probiotics in pregnancy suggested a
benefit in reducing the incidence of gestational diabetes (Laitinen
2008). Gestational diabetes is increasingly common and carries
significant risks for both maternal and infant health. Other types
of interventions, such as diet and exercise have proven difficult to
carry out and have mixed results (Dodd 2010; Streuling 2010).
Implementation of these interventions on a large scale practical
clinical level would prove challenging and expensive. Probiotic
supplementation, if beneficial, would be much easier to use in
clinical practice. A systematic review of the available literature
is required to establish whether there is any evidence to support
the use of probiotic supplements during pregnancy for preventing
gestational diabetes.
O B J E C T I V E S
To systematically assess the effects of probiotic supplements used
either alone or in combination with pharmacological and non-
pharmacological interventions on the incidence of gestational di-
abetes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised and cluster-randomised trials. Cluster-randomised
trials were eligible for inclusion but none were identified. Quasi-
randomised and cross-over design studies are not eligible for in-
clusion in this review. Studies presented only as abstracts with no
subsequent full report of study results would also have been ex-
cluded.
Types of participants
Studies that included pregnant women not previously diagnosed
with diabetes mellitus. Studies of women with GDM in a previ-
ous pregnancy but no evidence of diabetes mellitus or GDM in
the current pregnancy before entering the trial were eligible for
inclusion.
Types of interventions
Probiotic supplementation for prevention of gestational diabetes,
either alone or in combination with pharmacological (e.g. met-
formin) or non-pharmacological interventions (e.g. diet/lifestyle
interventions).
Probiotic supplementation (administered by any method) should
have been commencedprior to the diagnosis of gestational diabetes
and continued for any duration.
Comparison interventions of any type were eligible, e.g. placebo,
diet, exercise, pharmacological therapy (e.g. metformin).
Trials may have used other interventions in a comparison arm
or in combination with the probiotic. These other interventions
may have included pharmaceutical probiotic supplements as well
as food items supplemented with probiotics.
Types of outcome measures
Primary outcomes
Maternal
• Diagnosis of gestational diabetes mellitus, by the local
criteria where the study was performed.
Infant
• Macrosomia and large-for-gestational age.
• Death (including intrauterine fetal death (IUFD), stillbirth
and neonatal death).
Secondary outcomes
Maternal
• Pre-eclampsia.
• Changes in maternal gestational weight gain.
• Preterm delivery.
• Caesarean section.
• Long-term outcome - diagnosis of diabetes mellitus.
Infant
• Birthweight/birth centile, body composition.
• Shoulder dystocia.
• Admission to neonatal intensive care.
• Jaundice.
• Hypoglycaemia.
• Longitudinal data - rates of obesity, rates of diabetes
mellitus, body composition.
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Search methods for identification of studies
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting the Trials Search Co-ordinator (31 Au-
gust 2013).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. weekly searches of Embase;
4. handsearches of 30 journals and the proceedings of major
conferences;
5. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE and
Embase, the list of handsearched journals and conference pro-
ceedings, and the list of journals reviewed via the current aware-
ness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
Searching other resources
We searched the reference lists of all retrieved studies.
We did not apply any language restrictions.
Data collection and analysis
Selection of studies
Two review authors (Helen Barrett and Marloes Dekker Nitert)
independently assessed for inclusion all the potential studies we
identified as a result of the search strategy. We resolved any dis-
agreement through discussion or, if required, we consulted review
author Leonie Callaway.
Data extraction and management
We designed a form to extract data. For the one eligible study, two
review authors extracted the data using the agreed form. There
were no discrepancies in data extraction on the form. We entered
data into Review Manager software (RevMan 2012) and checked
it for accuracy.
All information regarding any of the above was clear, and we made
no attempt to contact authors of the original report to provide
further details.
Assessment of risk of bias in included studies
Two review authors (HLB, MDN) independently assessed risk of
bias for the one included study using the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (Hand-
book) (Higgins 2011).We resolved any disagreement by discussion
or by involving a third assessor.
(1) Random sequence generation (checking for possible
selection bias)
We described the method used to generate the allocation se-
quence in sufficient detail to assess whether it produced compara-
ble groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described the methods used to conceal allocation to interven-
tions prior to assignment and assessed whether the intervention
allocation could have been foreseen in advance of, or during re-
cruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described themethods used to conceal the allocation sequence
and determine whether intervention allocation could have been
foreseen in advance of, or during recruitment, or changed after
assignment.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
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(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described the methods used, if any, to blind study participants
and personnel fromknowledge of which intervention a participant
received. We considered that studies would be at low risk of bias if
they were blinded, or if we judged that the lack of blinding would
be unlikely to affect results. We assessed blinding separately for
different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
For the included study, we described, and for each outcome or
class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported, the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or could be supplied
by the trial authors, we re-included missing data in the analyses
which we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described how we investigated the possibility of selective out-
come reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described any important concerns we had about other possible
sources of bias.
We assessed whether the included study was free of other problems
that could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether the included study
was at high risk of bias, according to the criteria given in the
Handbook (Higgins 2011). With reference to (1) to (6) above, we
assessed the likelymagnitude and direction of the bias andwhether
we considered it was likely to impact on the findings. We planned
to explore the impact of the level of bias through undertaking
sensitivity analyses - see Sensitivity analysis.
Measures of treatment effect
Dichotomous data
For dichotomous data, we present results as summary risk ratio
with 95% confidence intervals.
Continuous data
For continuous data, we used the mean difference if outcomes
were measured in the same way between trials. We planned to use
the standardised mean difference to combine trials that measure
the same outcome, but used different scales.
Unit of analysis issues
Cluster-randomised trials
We did not identify any cluster-randomised trials for inclusion.
However, if we identify cluster-randomised trials in future up-
dates of this review, wewill include cluster-randomised trials in the
analyses along with individually-randomised trials. We will adjust
their effect measure using the methods described in theHandbook
using an estimate of the intracluster correlation co-efficient (ICC)
derived from the trial (if possible), from a similar trial or from a
study of a similar population. Where the cluster-randomised trial
properly accounts for the cluster design, wewill extract an estimate
of the effect measure directly. Where the cluster-randomised trial
does not properly account for the clustering, we will calculate the
effective sample size of the intervention and placebo groups by
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dividing the sample size by the design effect. The design effect is
1+ (m-1)*ICC where the ICC is the intracluster correlation coef-
ficient and m the average cluster size. The assessment of cluster-
randomised trials and the calculation of the effective sample size
will be performed with the assistance of a statistician. If we use
ICCs from other sources, we will report this and conduct sensi-
tivity analyses to investigate the effect of variation in the ICC. If
we identify both cluster-randomised trials and individually-ran-
domised trials, we plan to synthesise the relevant information.
We will consider it reasonable to combine the results from both
if there is little heterogeneity between the study designs and the
interaction between the effect of intervention and the choice of
randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a subgroup analysis to investigate the effects of the
randomisation unit.
Dealing with missing data
The one included study had a low level of attrition over the follow-
up period of 12months postpartum of 18.75%. In future updates,
we will explore the impact of including studies with high levels of
missing data in the overall assessment of treatment effect by using
sensitivity analysis.
For all outcomes, we carried out analyses, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all partic-
ipants randomised to each group in the analyses, and all partici-
pants were analysed in the group to which they were allocated, re-
gardless of whether or not they received the allocated intervention.
The denominator for each outcome in each trial was the number
randomised minus any participants whose outcomes are known
to be missing.
Assessment of heterogeneity
We planned to assess statistical heterogeneity in each meta-anal-
ysis using the T², I² and Chi² statistics. We would have regarded
heterogeneity as substantial if the I² was greater than 30% and
either the T² was greater than zero, or there was a low P value (less
than 0.10) in the Chi² test for heterogeneity.
Assessment of reporting biases
Given only one study has reported results, reporting biases analy-
sis has not yet been undertaken. In future updates of this review,
if there are 10 or more studies in the meta-analysis we will in-
vestigate reporting biases (such as publication bias) using funnel
plots. We will assess funnel plot asymmetry visually. If asymmetry
is suggested by a visual assessment, we will perform exploratory
analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2012). We planned to use fixed-effect meta-anal-
ysis for combining data where it was reasonable to assume that
studies were estimating the same underlying treatment effect: i.e.
where trials examined the same intervention, and the trials’ popu-
lations and methods were judged sufficiently similar. As only one
study has reported results, heterogeneity analysis has not yet been
undertaken. If more studies are included in future updates of this
review, and there is clinical heterogeneity sufficient to expect that
the underlying treatment effects differ between trials, or if sub-
stantial statistical heterogeneity is detected, we will use random-
effects meta-analysis to produce an overall summary, if an average
treatment effect across trials is considered clinically meaningful.
The random-effects summary will be treated as the average range
of possible treatment effects and we will discuss the clinical impli-
cations of treatment effects differing between trials. If the average
treatment effect is not clinically meaningful, we will not combine
trials.
If we use random-effects analyses, the results will be presented as
the average treatment effect with 95% confidence intervals, and
the estimates of T² and I².
For multi-arm trials, where there is a blinded placebo and un-
blinded control as well as treatment arm(s), the arms will be com-
pared separately without double counting of participants. Where
there is more than one treatment arm, each arm will be compared
separately to each of the other arms, without double counting of
participants.
Subgroup analysis and investigation of heterogeneity
Given only one study has reported results, subgroup analysis has
not yet been undertaken. If we identify substantial heterogeneity
in future updates as more trials are included, we will investigate it
using subgroup analyses and sensitivity analyses. We will consider
whether an overall summary ismeaningful, and if it is, use random-
effects analysis to produce it.
We plan to carry out the following subgroup analyses.
1. Maternal body mass index (BMI): normal/overweight/
obese. Subgroups defined by BMI. BMI will be categorised as
underweight (BMI less than 18.49), normal weight (18.5 to
24.99), overweight (25.00 to 29.99), obesity class I (30.00 to
34.99), class II (35.00 to 39.99), class III (greater than 40.00)
(WHO 2000; WHO Expert Consultation 2004). (underweight
versus normal versus overweight versus obese).
2. Past history of GDM (yes versus no).
3. Family history of type 2 diabetes (yes versus no).
4. Probiotic dose (more than 5 billion colony-forming units
(CFU) versus less than 5 billion CFU).
5. Probiotic bacterial species (each species versus others).
6. Probiotic duration of treatment (early pregnancy versus
more than 20 weeks).
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7. Probiotic mode of delivery (capsule versus other).
8. Probiotic frequency of administration (daily versus other).
Subgroup analysis will be restricted to the review’s primary out-
comes.
We will assess subgroup differences by interaction tests available
within RevMan (RevMan 2012). We will report the results of
subgroup analyses quoting the χ2 statistic and p-value, and the
interaction test I² value.
Sensitivity analysis
As only one study has reported results, sensitivity analysis has not
yet been undertaken. Sensitivity analysis will be carried out, where
necessary, to explore the influence of diagnostic criteria for GDM,
and high drop-out rates (more than 20%).
R E S U L T S
Description of studies
Results of the search
The search of the Cochrane Pregnancy and Childbirth Group’s
Trials Register retrieved eight citations. Review of the reference
lists of these studies, and the reference lists of citations found
in these studies yielded three further citations. The 11 citations
related to five independent randomised controlled trials. Only one
of these trials has reported results and has been included (Laitinen
2008). The other four studies are (Ahmed 2012; Callaway 2012;
McAuliffe 2012; Wickens 2012) are ongoing (see Characteristics
of ongoing studies) (see: Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Laitinen 2008 is the only study that has reported results and hence
is the only included study at this point. The study was a dou-
ble blind (for probiotics) randomised controlled trial carried out
in Finland, with three treatment arms: placebo/diet and placebo/
probiotic and diet. It included 256 women, of whom 7% were
obese and 21% overweight, without any metabolic or chronic dis-
ease. The study duration for the woman was from early pregnancy
until the end of exclusive breastfeeding, with follow-up until 24
months postpartum. The probiotic strains used were: Lactobacil-
lus rhamnosus GG, ATCC 53 103, Valio Ltd, Helsinki, Finland
and Bifidobacterium lactis Bb12, Chr. Hansen, Hoersholm, Den-
mark, 1010 colony-forming units/day each). Placebo was micro-
crystalline cellulose and dextrose anhydrate. The intensive dietary
counselling was to conform to the currently recommended preg-
nancy diet.
Excluded studies
There are no excluded studies.
Risk of bias in included studies
See Characteristics of included studies. The included study was
assessed to be at low risk of bias across all risk of bias domains. In
the future, when the results of the study that three of the authors
of this review are involved in (Helen Barrett, Marloes Dekker
Nitert and Leonie Callaway) (Callaway 2012), the fourth author
(Louise Conwell) will assess risk of bias with the assistance from the
Cochrane Pregnancy and Childbirth Group in order to minimise
the effects of conflict of interest.
Allocation
Laitinen 2008 used computer-generated block randomisation of
six women in each block. The randomisation list was generated
by a non-investigator statistician, and placed in sealed envelopes
(Laitinen 2008).
Blinding
Placebo/probiotic allocation was blind to both participants and
personnel, however, dietary therapy was not blinded to study staff
(Laitinen 2008).
Incomplete outcome data
There was minimal loss to follow-up at the time of testing for
gestational diabetes mellitus (Laitinen 2008).
Selective reporting
All findings reported (Laitinen 2008).
Other potential sources of bias
None.
Effects of interventions
Laitinen 2008 is the only currently completed study; the results
of the study are described below. We used two comparisons from
the three treatment arms in the study (probiotics + diet, placebo
+ diet and diet alone), halving the sample size and any relevant
denominators for binary data from probiotic group data.
Probiotics versus control (diet or placebo)
Primary outcomes
Maternal outcome
Diagnosis of gestational diabetes
The use of probiotics was associated with a reduction in the rate of
gestational diabetes (risk ratio (RR) 0.38, 95% confidence interval
(CI) 0.20 to 0.70) (Analysis 1.1) (Figure 2).
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Figure 2. Forest plot of comparison: 1 Primary maternal and infant outcomes: Probiotics vs placebo or diet,
outcome: 1.1 Diagnosis of gestational diabetes.
Infant outcome
Death (including miscarriage/IUFD/stillbirth/neonatal
death)
The use of probiotics did not alter the rates of death at any stage
of the pregnancy or in early infancy (RR 2.00, 95% CI 0.35 to
11.35) (Analysis 1.2) (Figure 3).
11Probiotics for preventing gestational diabetes (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Forest plot of comparison: 1 Primary maternal and infant outcomes: Probiotics vs placebo or diet,
outcome: 1.2 Miscarriage/IUFD/Stillbirth/Neonatal death.
Macrosomia/large-for-gestational-age babies
This outcome was not assessed (Analysis 1.3).
Secondary outcomes
Maternal outcomes
Rates of pre-eclampsia.
This outcome was not reported on (Analysis 2.1).
Maternal gestational weight gain
This outcome was not reported on (Analysis 2.2).
Preterm delivery
The use of probiotics did not affect the rates of preterm delivery
(RR 3.27, 95% CI 0.44 to 24.43) (Analysis 2.3) (Figure 4) .
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Figure 4. Forest plot of comparison: 2 Secondary maternal outcomes: probiotics vs placebo or diet,
outcome: 2.3 Preterm delivery < 37 weeks’ gestation.
Caesarean section
Probiotic supplementation did not change the rate of caesarean
section (RR 1.23, 95% CI 0.65 to 2.32) (Analysis 2.4) ( Figure
5).
Figure 5. Forest plot of comparison: 2 Secondary maternal outcomes: probiotics vs placebo or diet,
outcome: 2.4 Caesarean section.
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Long-term risk of diabetes mellitus
This outcome was not reported on (Analysis 2.5).
Infant outcomes
Infant birthweight, birth centile and body composition
Infant birthweight was assessed and there was a reduction of birth-
weight in the women taking probiotics supplementation (mean
difference (MD) -127.71 g, 95% CI -251.37 to -4.06) (Analysis
3.1) (Figure 6). Birth centile (Analysis 3.2) and infant body com-
position Analysis 3.3 were not reported on.
Figure 6. Forest plot of comparison: 3 Secondary infant outcomes: probiotics vs placebo or diet, outcome:
3.1 Birthweight.
Shoulder dystocia
This outcome was not reported (Analysis 3.4).
Admission to neonatal intensive care unit
This outcome was not reported (Analysis 3.5).
Jaundice
This outcome was not reported (Analysis 3.6).
Hypoglycaemia
This outcome was not reported (Analysis 3.7).
Long-term outcomes
The outcomes childhood obesity (Analysis 3.8), rate of diabetes
mellitus (Analysis 3.9) and childhood body composition (Analysis
3.10) were not reported in the included study.
D I S C U S S I O N
Summary of main results
We included one study, involving 256women.However, this study
does show a 60% decrease in the rate of diagnosis of gestational di-
abetes mellitus in women taking probiotics from early pregnancy.
No further analysis was done at this time due to there being only
one completed study. No subgroup analyses have been undertaken
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as yet for the same reason. This will be addressed when the results
of the ongoing studies are reported.
Overall completeness and applicability of
evidence
The one completed study (Laitinen 2008) reported multiple ma-
ternal and infant outcomes across their various publications. They
did not report on all the primary and secondary outcomemeasures
to be included in this systematic review.
Quality of the evidence
The one study completed (Laitinen 2008) is a double blind, ran-
domised trial of 256 women who were followed up for 12 months
postpartum. The positive results of this study require confirma-
tion with other studies also in populations at increased risk for
developing gestational diabetes mellitus. There are four studies
currently ongoing.
Potential biases in the review process
This review addresses a new area of research with only a limited
number of studies identified. The search for studies in this area was
performed using the Cochrane Pregnancy and Childbirth Group’s
Trials Register which is updated weekly to monthly with infor-
mation from the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, Embase, handsearches from 30 jour-
nals and conference proceeding of major conferences and alerts for
a further 44 journals. It is unlikely that studies that have concluded
have been missed, however, ongoing studies that have not been
registered in clinical trial registries could be missing. This would
not alter the conclusion of the current review since there would
not be any results to analyse yet. There was a low risk of bias within
the one completed study for selection bias, performance bias, re-
porting bias and attrition bias. The data were extracted from the
six publications relating to this study, however, the investigators
were not contacted to obtain additional data. The data analysis for
this study has necessarily been limited until further studies with
relevant outcomes are reported.
Agreements and disagreements with other
studies or reviews
Since this review addresses a new area of research, there have only
been two reviews of the impact of probiotics on gestational diabetes
mellitus, one written by the authors of this review (Barrett 2012)
and one with a broader focus on maternal outcomes (Lindsay
2013). The inclusion criteria were slightly different between the
reviews but the outcomes reported are in agreement with the ones
reported in this Cochrane review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results from the included study (involving 256 women) sug-
gest that probiotics may reduce the risk of gestational diabetes
mellitus. This requires confirmation with further studies and es-
pecially in populations with higher risks of developing gestational
diabetes mellitus. There are inadequate data to determine the ef-
fect of probiotics on fetal or neonatal death and macrosomia.
Implications for research
Further studies are needed to confirm the results of Laitinen
2008. Probiotics may have beneficial effects on other outcomes
than gestational diabetes mellitus such as rates of macrosomia/
large-for-gestational-age infants, infant body composition, mater-
nal pre-eclampsia, delivery by caesarean section, and future risk of
metabolic disease for mother and infant. These outcomes should
be addressed in further studies. Potential additional aspects to be
addressed in future studies include dosage of the probiotics, strain
specificity, storage conditions and shelf life of the probiotics.
A C K N OW L E D G E M E N T S
As part of the pre-publication editorial process, this review has
been commented on by three peers (an editor and two referees
who are external to the editorial team), a member of the Pregnancy
and Childbirth Group’s international panel of consumers and the
Group’s Statistical Adviser.
The National Institute for Health Research (NIHR) is the largest
single funder of the Cochrane Pregnancy and Childbirth Group.
The views and opinions expressed therein are those of the authors
and do not necessarily reflect those of the NIHR, NHS or the
Department of Health.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Laitinen 2008
Methods DESIGN: randomised controlled trial.
BLINDING: double blind for probiotics/placebo, single blind for dietary intervention
UNIT OF COMPARISON: individuals.
DURATION: supplementation with probiotic/placebo from early pregnancy until the
end of exclusive breastfeeding
FOLLOW-UP: 24 months postpartum.
LOCATION: Finland.
Participants TOTAL NUMBER: 256.
No metabolic or chronic diseases.
7% of women were obese, 21% were overweight.
Interventions PROBIOTIC: Lactobacillus rhamnosus GG, ATCC 53 103, Valio Ltd, Helsinki, Fin-
land and Bifidobacterium lactis Bb12, Chr. Hansen, Hoersholm, Denmark, 1010 colony-
forming units/d each).
PLACEBO: microcrystalline cellulose and dextrose anhydrate.
DIETARY: intensive dietary counselling aiming to conform to currently recommended
pregnancy diet
Outcomes PRIMARY: maternal glucose metabolism as measured by plasma glucose, blood HbA1c,
serum insulin andHOMAandQUICKI indices at baseline, third trimester of pregnancy,
1, 6 and 12 months postpartum
Notes NCT00167700
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated block randomisation
of 6 women. The use of only 1 block size
could make it possible to guess the ran-
domisation of the dietary intervention of
the last individuals of each block. However,
since this randomisation was only blinded
to the participants and not the study per-
sonnel, the selection bias risk is still consid-
ered to be low
Allocation concealment (selection bias) Low risk Randomisation list generated by a non-in-
vestigator statistician, sealed envelopes
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Laitinen 2008 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo/probiotic allocation was blind to
both participants and personnel, dietary
therapy was not blinded to personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All personnel who handled or analysed
blood samples were blind to the interven-
tion
Incomplete outcome data (attrition bias)
All outcomes
Low risk Minimal loss to follow-up by assessment of
glucose tolerance. Total loss to follow-up
was 18.75% by 1 year postpartum
Selective reporting (reporting bias) Low risk Reported all outcomes they intended to re-
port.
Other bias Low risk No other biases detected.
Hb: haemoglobin
HOMA: homeostasis model assessment
QUICKI: quantitative insulin sensitivity check index
Characteristics of ongoing studies [ordered by study ID]
Ahmed 2012
Trial name or title Probiotics (Lactobacillus Rhamnosus) in reducing glucose intolerance during and after pregnancy (GRIP)
Methods DESIGN: randomised controlled trial.
BLINDING: double blind for probiotics/placebo.
DURATION: supplementation with probiotic/placebo from early pregnancy until delivery
FOLLOW-UP: 6 weeks postpartum.
LOCATION: Pakistan.
Participants Women in early pregnancy, 18-45 years with 1 or more of: BMI > 23 OR family history of diabetes in first-
degree relatives, or maternal age > 35
Interventions PROBIOTIC: Lactobacillus rhamnosus 1010 colony-forming units/d each.
Outcomes Glucose tolerance by OGTT using ADA guidelines between 24-28 weeks’ gestation and at 6-8 weeks’ post-
partum
Starting date October 2011.
Contact information Principal Investigator: Bilal Ahmed, MSc, Aga Khan University
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Ahmed 2012 (Continued)
Notes NCT01436448
Callaway 2012
Trial name or title SPRING: an RCT study of probiotics in the prevention of gestational diabetes mellitus in overweight and
obese women
Methods DESIGN: randomised controlled trial.
BLINDING: double blind for probiotics/placebo.
DURATION: supplementation with probiotic/placebo from early pregnancy until delivery
LOCATION: Australia.
Participants Overweight and obese women, < 16 weeks’ gestation at study entry, 18-45 years
Interventions PROBIOTIC: Lactobacillus rhamnosusGG and Bifidobacterium lactis Bb12, Chr. Hansen, Hoersholm, Den-
mark, 109 colony-forming units/d each).
PLACEBO: microcrystalline cellulose and dextrose anhydrate.
Outcomes Glucose tolerance by OGTT using IADPSG guidelines between 24-28 weeks’ gestation
Starting date November 2012.
Contact information A/Prof Leonie Callaway, The University of Queensland.
Notes ACTRN12611001208998
McAuliffe 2012
Trial name or title Probiotics in Pregnancy Study (ProP Study).
Methods DESIGN: randomised controlled trial.
BLINDING: double blind for probiotics/placebo.
DURATION: supplementation with probiotic/placebo from early pregnancy until delivery
LOCATION: Ireland.
Participants 1) Part A: Prevention of GDM: obese women aged 18-45 years, < 22 weeks’ gestation
2) Part B: Treatment of GDM: women with GDM or Impaired glucose tolerance, any BMI, aged 18-45
years, < 36 weeks’ gestation
Interventions PROBIOTIC:
PLACEBO:
Outcomes 1) Part A: difference between the control and probiotic groups in fasting blood glucose.
2) Part B: difference between the control and probiotic groups in fasting blood glucose
Starting date 20/02/2012.
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McAuliffe 2012 (Continued)
Contact information Prof Fionnuala McAuliffe.
Notes ISRCTN97241163
Wickens 2012
Trial name or title A randomised placebo-controlled trial of the effects of the probiotic Lactobacillus rhamnosus HN001 taken
from the 1st trimester of pregnancy till 6 months postpartum, if breastfeeding, on the development of eczema
and atopic sensitisation in infants by age 12 months. (PIP)
Methods DESIGN: randomised controlled trial.
BLINDING: double blind for probiotics/placebo.
DURATION: supplementation with probiotic/placebo from early pregnancy until 6 months postpartum
LOCATION: New Zealand.
Participants Women 14-16 weeks’ gestation, if they or the infant’s father has a history of asthma, eczema or allergic rhinitis.
No weight or age limits
Interventions PROBIOTIC: Lactobacillus rhamnosusHN001 administered daily as capsules. The starting viable cell number
is 6.1x1010 CFU* per g, which equates to a dose per capsule of 9.2x109 CFU.
PLACEBO: the placebo will be identical in appearance and smell and contain maltodextran only
Outcomes PRIMARY: infant eczema and atopic sensitisation at age 12 months
SECONDARY: gestational diabetes mellitus (OGTT 75g using ADIPS criteria), bacterial vaginosis, group
B strep, breast milk cytokines, maternal and infant anthropometry, maternal lipids and incretin hormones
Starting date 20/12/2012.
Contact information Dr Kristin Wickens, University of Otago, New Zealand.
Notes ACTRN12612000196842
AFA: American Diabetes Association
ADIPS: Australasian Diabetes in Pregnancy Society
BMI: body mass index
CFU: colony forming unit
GDM: gestational diabetes mellitus
IADPSG: International Association of the Diabetes and Pregnancy Study Groups
OGTT: oral glucose tolerance test
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Primary maternal and infant outcomes: probiotics versus placebo or diet
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Diagnosis of gestational diabetes 1 225 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.20, 0.70]
1.1 Probiotics versus placebo 1 111 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.16, 0.92]
1.2 Probiotics versus diet 1 114 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.15, 0.89]
2 Miscarriage/IUFD/Stillbirth/
Neonatal death
1 256 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.35, 11.35]
2.1 Probiotics versus diet 1 127 Risk Ratio (M-H, Fixed, 95% CI) 6.0 [0.25, 144.22]
2.2 Probiotics versus placebo 1 129 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.09, 10.72]
3 Macrosomia 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.1 Probiotics versus placebo 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Probiotics versus diet 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Secondary maternal outcomes: probiotics versus placebo or diet
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pre-eclampsia 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.1 Probiotics versus placebo 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Probiotics versus diet 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Gestational weight gain 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.1 Probiotic versus placebo 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Probiotic versus diet 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Preterm delivery < 37 weeks’
gestation
1 238 Risk Ratio (M-H, Fixed, 95% CI) 3.27 [0.44, 24.43]
3.1 Probiotics versus placebo 1 119 Risk Ratio (M-H, Fixed, 95% CI) 1.98 [0.13, 30.76]
3.2 Probiotics versus diet 1 119 Risk Ratio (M-H, Fixed, 95% CI) 5.85 [0.24, 140.54]
4 Caesarean section 1 218 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.65, 2.32]
4.1 Probiotics versus placebo 1 109 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.51, 3.11]
4.2 Probiotics versus diet 1 109 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.49, 2.93]
5 Maternal diagnosis of diabetes
mellitus postpartum
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.1 Probiotics versus placebo 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Probiotics versus diet 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 3. Secondary infant outcomes: probiotics versus placebo or diet
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Birthweight 1 256 Mean Difference (IV, Random, 95% CI) -127.71 [-251.37, -
4.06]
1.1 Probiotics versus placebo 1 128 Mean Difference (IV, Random, 95% CI) -144.0 [-320.46, 32.
46]
1.2 Probiotics versus diet 1 128 Mean Difference (IV, Random, 95% CI) -112.0 [-285.33, 61.
33]
2 Birthweight centile 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.1 Probiotics versus placebo 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Probiotics versus diet 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Percentage body fat (neonatal) 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.1 Probiotics versus placebo 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Probiotics versus diet 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Shoulder dystocia 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.1 Probiotics versus placebo 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Probiotics versus diet 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Admission to neonatal intensive
care
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.1 Probiotics versus placebo 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Probiotics versus diet 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Jaundice 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.1 Probiotics versus placebo 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Probiotics versus diet 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Hypoglycaemia 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.1 Probiotics versus placebo 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Probiotics versus diet 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Childhood obesity 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.1 Probiotics versus placebo 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Probiotics versus diet 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Infant diagnosis of diabetes
mellitus
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.1 Probiotics versus placebo 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Probiotics versus diet 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Percentage body fat (childhood) 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.1 Probiotics versus placebo 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 Probiotics versus diet 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Primary maternal and infant outcomes: probiotics versus placebo or diet,
Outcome 1 Diagnosis of gestational diabetes.
Review: Probiotics for preventing gestational diabetes
Comparison: 1 Primary maternal and infant outcomes: probiotics versus placebo or diet
Outcome: 1 Diagnosis of gestational diabetes
Study or subgroup Probiotic Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Probiotics versus placebo
Laitinen 2008 5/38 25/73 48.7 % 0.38 [ 0.16, 0.92 ]
Subtotal (95% CI) 38 73 48.7 % 0.38 [ 0.16, 0.92 ]
Total events: 5 (Probiotic), 25 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.032)
2 Probiotics versus diet
Laitinen 2008 5/38 27/76 51.3 % 0.37 [ 0.15, 0.89 ]
Subtotal (95% CI) 38 76 51.3 % 0.37 [ 0.15, 0.89 ]
Total events: 5 (Probiotic), 27 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.23 (P = 0.025)
Total (95% CI) 76 149 100.0 % 0.38 [ 0.20, 0.70 ]
Total events: 10 (Probiotic), 52 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 3.09 (P = 0.0020)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
0.01 0.1 1 10 100
Favours [probiotic] Favours [placebo]
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Analysis 1.2. Comparison 1 Primary maternal and infant outcomes: probiotics versus placebo or diet,
Outcome 2 Miscarriage/IUFD/Stillbirth/Neonatal death.
Review: Probiotics for preventing gestational diabetes
Comparison: 1 Primary maternal and infant outcomes: probiotics versus placebo or diet
Outcome: 2 Miscarriage/IUFD/Stillbirth/Neonatal death
Study or subgroup Probiotic Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Probiotics versus diet
Laitinen 2008 1/42 0/85 20.0 % 6.00 [ 0.25, 144.22 ]
Subtotal (95% CI) 42 85 20.0 % 6.00 [ 0.25, 144.22 ]
Total events: 1 (Probiotic), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
2 Probiotics versus placebo
Laitinen 2008 1/43 2/86 80.0 % 1.00 [ 0.09, 10.72 ]
Subtotal (95% CI) 43 86 80.0 % 1.00 [ 0.09, 10.72 ]
Total events: 1 (Probiotic), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 85 171 100.0 % 2.00 [ 0.35, 11.35 ]
Total events: 2 (Probiotic), 2 (Placebo)
Heterogeneity: Chi2 = 0.79, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.43)
Test for subgroup differences: Chi2 = 0.78, df = 1 (P = 0.38), I2 =0.0%
0.01 0.1 1 10 100
Favours [probiotic] Favours [placebo]
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Analysis 2.3. Comparison 2 Secondary maternal outcomes: probiotics versus placebo or diet, Outcome 3
Preterm delivery < 37 weeks’ gestation.
Review: Probiotics for preventing gestational diabetes
Comparison: 2 Secondary maternal outcomes: probiotics versus placebo or diet
Outcome: 3 Preterm delivery < 37 weeks’ gestation
Study or subgroup Probiotic Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Probiotics versus placebo
Laitinen 2008 1/40 1/79 66.5 % 1.98 [ 0.13, 30.76 ]
Subtotal (95% CI) 40 79 66.5 % 1.98 [ 0.13, 30.76 ]
Total events: 1 (Probiotic), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.63)
2 Probiotics versus diet
Laitinen 2008 1/40 0/79 33.5 % 5.85 [ 0.24, 140.54 ]
Subtotal (95% CI) 40 79 33.5 % 5.85 [ 0.24, 140.54 ]
Total events: 1 (Probiotic), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
Total (95% CI) 80 158 100.0 % 3.27 [ 0.44, 24.43 ]
Total events: 2 (Probiotic), 1 (Placebo)
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Chi2 = 0.26, df = 1 (P = 0.61), I2 =0.0%
0.01 0.1 1 10 100
Favours [probiotic] Favours [placebo]
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Analysis 2.4. Comparison 2 Secondary maternal outcomes: probiotics versus placebo or diet, Outcome 4
Caesarean section.
Review: Probiotics for preventing gestational diabetes
Comparison: 2 Secondary maternal outcomes: probiotics versus placebo or diet
Outcome: 4 Caesarean section
Study or subgroup Probiotic Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Probiotics versus placebo
Laitinen 2008 6/33 11/76 48.6 % 1.26 [ 0.51, 3.11 ]
Subtotal (95% CI) 33 76 48.6 % 1.26 [ 0.51, 3.11 ]
Total events: 6 (Probiotic), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
2 Probiotics versus diet
Laitinen 2008 6/32 12/77 51.4 % 1.20 [ 0.49, 2.93 ]
Subtotal (95% CI) 32 77 51.4 % 1.20 [ 0.49, 2.93 ]
Total events: 6 (Probiotic), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Total (95% CI) 65 153 100.0 % 1.23 [ 0.65, 2.32 ]
Total events: 12 (Probiotic), 23 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
0.01 0.1 1 10 100
Favours [probiotic] Favours [placebo]
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Analysis 3.1. Comparison 3 Secondary infant outcomes: probiotics versus placebo or diet, Outcome 1
Birthweight.
Review: Probiotics for preventing gestational diabetes
Comparison: 3 Secondary infant outcomes: probiotics versus placebo or diet
Outcome: 1 Birthweight
Study or subgroup Probiotic Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Probiotics versus placebo
Laitinen 2008 43 3467 (449.7091) 85 3611 (537.7964) 49.1 % -144.00 [ -320.46, 32.46 ]
Subtotal (95% CI) 43 85 49.1 % -144.00 [ -320.46, 32.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
2 Probiotics versus diet
Laitinen 2008 42 3467 (449.7091) 86 3579 (508.3945) 50.9 % -112.00 [ -285.33, 61.33 ]
Subtotal (95% CI) 42 86 50.9 % -112.00 [ -285.33, 61.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.21)
Total (95% CI) 85 171 100.0 % -127.71 [ -251.37, -4.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.02 (P = 0.043)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
-100 -50 0 50 100
Favours [probiotic] Favours [placebo]
A D D I T I O N A L T A B L E S
Table 1. Diagnostic criteria for GDM
IADPSG (ACOG
Committee 2005) #
ADIPS ## (Hoffman
1998)
ADA ### (ADA criteria)
OGTT (g) 75 75 100
Fasting (mmol/L) 5.11 5.5 5.33
1 Hour (mmol/L) 10 - 10
2 Hour (mmol/L) 8.5 8 * 8.6
3 Hour (mmol/L) - - 7.8
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# International Association of the Diabetes and Pregnancy Study Groups has separate criteria for diabetes diagnosed during pregnancy
(as compared to gestational diabetes) to differentiate cases where diabetes is probably pre-existing and does not resolve postpartum.
## Australasian Diabetes in Pregnancy Society
### American Diabetes Association
OGTT: oral glucose tolerance test
* In New Zealand, the 2-hour post glucose diagnostic cut-off is 9 mmol/L
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